Stock Data
$3.59 (2.25%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DRUG MANUFACTURERS - SPECIALTY & GENERIC
Neurocrine Biosciences Inc is a biopharmaceutical company based in San Diego, California, focusing on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio includes INGREZZA for tardive dyskinesia, ALKINDI for adrenal insufficiency, and several products for conditions like Huntington’s disease, endometriosis, and uterine fibroids. The company is also advancing a range of candidates for conditions such as developmental and epileptic encephalopathy, major depressive disorder, and schizophrenia, among others. Neurocrine Biosciences maintains collaborations with various pharmaceutical companies to enhance its research and development efforts.
Neurocrine demolished EPS expectations by 44% and hiked full-year INGREZZA guidance after the $2.9 billion Soleno acquisition added $54 million in revenue and positioned the biotech's pipeline for major 2027 clinical readouts in depression and schizophrenia.
92 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
